Vytrus BiotechXMAD:VYT +0.57%69 Gross Margin % is 106.11% as of Dec. 2025, which is 9% below its 10-year median of 116.20. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 730 Biotechnology companies, Vytrus Biotech ranks better than 99.04% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vytrus Biotech had a gross margin of 106.11% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vytrus Biotech Gross Margin % Related Terms
Vytrus Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Vytrus Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vytrus Biotech (XMAD:VYT) has a Gross Margin % of 106.11% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Vytrus Biotech and its competitors. This is near median its historical median of 116.20. Over the past decade, Vytrus Biotech's Gross Margin % has ranged from 105.46 to 131.98. According to the industry distribution chart, Vytrus Biotech ranks #7 out of 730 companies in the Biotechnology industry, placing it in the top 1%.
Is Vytrus Biotech's Gross Margin % too high?
Vytrus Biotech's current Gross Margin % of 106.11% is near median its 10-year median of 116.20. Over the past 10 years, this metric has ranged from a low of 105.46 to a high of 131.98. The Biotechnology industry median Gross Margin % is 60.91. Vytrus Biotech's value of 106.11% is 74.2% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #7 out of 730 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #7 out of 730 companies for Gross Margin %. This places Vytrus Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Vytrus Biotech's value of 106.11% is 74.2% above this benchmark. Historically, Vytrus Biotech's own Gross Margin % has ranged from 105.46 to 131.98 over the past decade. While the company's 10-year median is 116.20 vs. the industry median of 60.91, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Gross Margin % of 106.11% is 74.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Gross Margin % is 106.11%, which is near median its own 10-year median of 116.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.50 — trading 215.9% above its estimated fair value. The current Gross Margin % is 106.11%, which is near median its 10-year median of 116.20 and 74.2% above the Biotechnology industry median of 60.91. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Gross Margin % is 106.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.50 is trading 215.9% above its estimated GF Value™ of €5.54.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Gross Margin %: 106.11% (near median its 10-year median of 116.20)
GF Value™: €5.54 vs. price of €17.50 (215.9% above fair value)
Industry Position: 74.2% above the Biotechnology median (#7 of 730)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
